Neoadjuvant Gemcitabine Plus Cisplatin With or Without Durvalumab in Resectable Biliary Tract Cancer

NCT04308174 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

45

Enrollment

OTHER

Sponsor class

Conditions

Biliary Tract Neoplasms
Gallbladder Cancer
Cholangiocarcinoma

Interventions

DRUG: Durvalumab + Gem/Cis
DRUG: Gem/Cis

Sponsor

Asan Medical Center

Collaborators

[object Object]